EnGeneIC launches clinical development strategy for EDV Nanocell Technology
In June 2014, EnGeneIC completed a Phase 1 trial in recurrent glioma in Australia and now plans to submit an IND and commence the U.S. clinical program in
Akeso has received approval from China’s National Medical Products Administration (NMPA) for gumokimab (AK111), an anti-Interleukin-17 (IL-17) monoclonal antibody, to treat adults with moderate-to-severe plaque psoriasis.
This first step towards identification of new classes of targeted anti-infectious drugs was achieved only 9 months after signature of a discovery collaboration will trigger the payment of
Preliminary data from the Cook/Selexis-sponsored proof-of-concept program has been published in the June issue of BioProcess International in an article titled, "Rapid Development and Scale-Up Through Strategic Partnership: